TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05487495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5 CAR T (CT125B)
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
Study: NCT04895280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1

Intervention type: DRUG
Group type: OTHER
Intervention: Marcaine
Description: Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine

Intervention type: DRUG
Group type: OTHER
Intervention: Marcaine
Description: Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine

Intervention type: DRUG
Group type: OTHER
Intervention: Kenalog
Description: Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.
Study: NCT04630730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)
Description: 1 dose of VPM1002BC, live, 1-19.2 x 108 colony forming units (CFU) on day 1, 8 (+/- 1 day) and 15 (+/- 1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Neoadjuvant immunotherapy with atezolizumab, 4 cycles 1200 mg fixed dose iv infusion on d1 q3w starting 4-16 weeks after date of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Neoadjuvant chemotherapy with cisplatin: 4 cycles 70mg/m2 iv infusion on d1 q3w (starting on d22)
Study: NCT06067659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy+Kinesiology taping
Description: Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
Study: NCT03274375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA session
Description: 10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~* at least 1 day before each IA session~* the last injection will occur after the last session IA (minimum one day after)
Study: NCT04593160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium- acetaminophen combination
Description: Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Description: Preoperative single dose of diclofenac potassium(50mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperative single dose of placebo
Study: NCT04630730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Neoadjuvant chemotherapy with gemcitabine: 4 cycles 1000 mg/m2 iv infusion on d1 and d8 q3w (starting on d22)
Study: NCT06222047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast milk
Description: give breast milk before the OG catheter insertion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dextrose
Description: give %20 dextrose before the OG catheter insertion
Study: NCT06137547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypotension prediction index (HPI)
Description: The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.
Study: NCT06324578

Intervention type: DIAGNOSTIC_TEST
Intervention: AT Testing
Description: Analysis of blood specimens and neck ultrasonography
Study: NCT05302232

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: depomedrone 40mg/ml + 1% lidocaine
Description: Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: depomedrone 40mg/ml+ 0.9% saline
Description: Response to intra-articular injection of steroid only as a placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: painDETECT questionnaire
Description: painDETECT questionnaire

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: painDETECT questionnaire
Description: painDETECT questionnaire
Study: NCT04662632

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VT-X7 Treatment System with Tobramycin Sulfate
Description: Seven-day local antibiotic irrigation with tobramycin sulfate via the VT-X7 Knee or Hip Spacer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage exchange arthroplasty
Description: Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
Study: NCT01021163

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine, saline
Description: Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
Study: NCT06430255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education
Description: Program for treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser-guided Supervised Exercise
Description: Program for treatment
Study: NCT05571150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyad-focused strategy training intervention
Description: The program consists of five critical ingredients: shared decision making, self-selected goals, self-evaluation of performance, strategy development and implementation, and therapeutic guided discovery.~Trained research therapists will deliver the intervention to the survivor-caregiver dyads on a one-to-two base at the participants' home or in a quiet room at our collaborative hospitals. The therapist will ask the dyad to identify 3 to 5 shared participation goals and provide them the global strategy (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-control intervention
Description: The topics of the education will cover: (1) secondary stroke prevention; (2) prevention and management of comorbidities; (3) managing emotions and behaviors; (3) medications and personal care; (4) finances and transportation; and (5) home and community-based participation.
Study: NCT06007170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPIRION Laryngeal Pacemaker System Implantation and follow-up
Description: Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives
Study: NCT04662632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage exchange arthroplasty
Description: Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VT-X7 Treatment System with Vancomycin Hydrochloride
Description: Seven-day local antibiotic irrigation with vancomycin hydrochloride via the VT-X7 Knee or Hip Spacer.
Study: NCT05890586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study: NCT02545127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merotocin
Description: Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
Study: NCT06514651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAQ-001
Description: MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade
Study: NCT02545127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
Study: NCT05376553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350mg intravenous infusion over 30 minutes
Study: NCT04825847

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS monitor
Description: Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at \[0.8-1.2\] MAC.
Study: NCT05360394

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Coated Balloon
Description: CAS treated with PCB only

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated Balloon and Stent Graft
Description: CAS treated with PCB first before deployment of stent graft
Study: NCT05376553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350mg intravenous infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)
Study: NCT06514651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAQ-001
Description: MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAQ-001
Description: MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAQ-001
Description: MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAQ-001
Description: MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
Study: NCT06559605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zirconia barrier
Description: barrier membrane used for guided bone regeneration and augmentation of ridge defect

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: titanium mesh
Description: barrier membrane used for guided bone regeneration
Study: NCT05970289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα will be given via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα will be given via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα will be given via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα will be given via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835
Description: BRII-835 will be given via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835
Description: BRII-835 will be given via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835
Description: BRII-835 will be given via subcutaneous injection
Study: NCT05956977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resection with help of 3D ultrasound
Description: see above
Study: NCT05376553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)
Study: NCT06475053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NaturalVue Enhanced Multifocal 1 Day contact lens
Description: Daily disposable multifocal contact lens
Study: NCT05349370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotopically labeled lactate
Description: A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn
Study: NCT02454764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + Interferon alpha 2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil Fumarate
Study: NCT04644757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: The study will employ an individual receptive relaxation music method with participants selecting music based on their preference from a selection of various styles from the MUSIC CARE© app. The music intervention will last 20 minutes per session and will be administered twice daily for 4 consecutive days. Participants will be given an electronic tablet with the MUSIC CARE© app loaded on it and trained on how to access the app to select their preferred style of music.Participants will be instructed to use the provided headphone during all interventions and to sit in a quiet area while wearing an ocular mask to avoid distractions.The PI will remotely monitor each of the music intervention sessions in real-time monitoring via a secured video conferencing interface to ensure adherence to study protocol.
Study: NCT06475053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MiSight 1 Day contact lens
Description: Daily disposable dual-focus contact lens
Study: NCT06514651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
Study: NCT06426225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General Anesthesia Applied Group 2 Patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Aneshtesia
Description: Spinal Anesthesia and Ketofol Sedation Applied Group 1 Patients.
Study: NCT05069688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Patients will receive standard TB and HIV treatment, however, for two weeks (study weeks 20-21) the dose of rifampicin will be increased from standard-dose to high-dose to assess pharmacokinetics and safety
Study: NCT06561607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for Injection
Description: TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)
Description: Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment.~* Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle.~* Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly.~* Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle.
Study: NCT06562400

Intervention type: DIETARY_SUPPLEMENT
Intervention: Palmitoyl ethanolamide
Description: PEA supplementation (600mg twice a day for three months)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Palmitoyl ethanolamide
Description: PEA supplementation (600mg twice a day for three months)

Intervention type: BEHAVIORAL
Intervention: Ketogenic diet
Description: Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates
Study: NCT06467513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride injection
Description: The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride injection
Description: The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.
Study: NCT06314035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD Patient Decision Aid
Description: Participants in this group will receive two 60-minute intervention sessions in one month. The COPD PDA consists of three main parts: The first component, clinical counselling, guides the participants in reviewing the common EOL scenarios. The second component, an evidence-based decision aid, is presented as an option grid in a booklet and a video to provide information about outcome probabilities of various treatment options and survival estimates in a balanced and unbiased manner. The information is presented in plain language for laypersons. The third component, decision coaching, introduces the concept of ACP and guides deliberation through value clarification.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General Health Coaching Intervention
Description: The participants in the control group will receive two 60-minute health coaching sessions developed by the PI for another project as an attention placebo control. Trained research personnel will use the same amount of interaction time and similar formats to avoid threats to the study's internal validity. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes. The trained research personnel will give the guidebook consisting of general self-management advice to participants in this group.
Study: NCT05629338

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous Spray Dried Plasma
Description: Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous Spray Dried Plasma
Description: Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers
Study: NCT05540691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wear noise-cancelling earphones
Description: Intervention of wearing noise-canceling earphones after general anesthesia